Student or educator? Sign up with your school email and get 6 months of Pro free.
CoChat
Cited by 185

The DOI matches its Crossref record; 1 of the 1 references it cites were found in a registry or an index.

Results of a Prospective Phase 2 Pilot Trial of 177Lu–PSMA-617 Therapy for Metastatic Castration-Resistant Prostate Cancer Including Imaging Predictors of Treatment Response and Patterns of Progression

Emmett, Louise, Crumbaker, Megan, Ho, Bao, Willowson, Kathy, Eu, Peter, Ratnayake, Lalith, Epstein, Richard, Blanksby, Ashley, Horvath, Lisa, Guminski, Alex, Mahon, Kate, Gedye, Craig, Yin, Charlotte, Stricker, Phillip, Joshua, Anthony M. · 2019 · Clinical Genitourinary Cancer

Abstract

Background 177Lu–PSMA‐617 (Lu‐PSMA) is an emerging therapy in men with metastatic castration‐resistant prostate cancer. Paired theranostic agents have the potential to visually identify phenotypes that will respond to targeted therapy. This study examined the value of 68Ga‐HBEDD PSMA‐11; prostate‐specific membrane antigen (PSMA) positron emission tomography (PET) in predicting treatment response and disease progression in Lu‐PSMA therapy within the context of a phase 2 prospective pilot trial. Patients and Methods Men with progressive, symptomatic metastatic castration‐resistant prostate cancer previously treated with antiandrogens (abiraterone and/or enzalutamide) and taxane‐based chemotherapy were prospectively enrolled. Eligibility criteria included uptake on PSMA PET above or equal to liver activity, with no 18F‐Fluoro–deoxyglucose (FDG) PET‐discordant disease. Men received up to 4 cycles of Lu‐PSMA at 6 weekly intervals. Repeat FDG/PSMA PET imaging was performed after completion of therapy or at prostate‐specific antigen (PSA) progression. The study assessed treatment response to Lu‐PSMA using PSA response and correlated treatment response (PSA) to molecular imaging parameters at enrollment. Results Fourteen of 18 men screened underwent Lu‐PSMA therapy. Ten (71%) of 14 had a PSA response (mean reduction, 59%). A ≥ 50% reduction in PSA occurred in 5 (36%), and ≥ 30% in 9 (64%). PSMA PET standardized uptake value (SUV) at screening was predictive of ≥ 30% PSA reduction: SUV max value 17 ± 9 versus 44 ± 15 (P < .007), and PSMA SUV mean 6 ± 4 versus 10 ± 4 (P < .04). FDG parameters alone, and volume or site of disease did not predict PSA response. No imaging parameters predicted ≥ 50% PSA reduction. Nine of 14 men were reimaged after treatment, revealing 3 distinct patterns of progression. Conclusion PSMA PET plays an important role in predicting treatment response to Lu‐PSMA and in identifying subsequent patterns of failure, which may aid in determining the next best treatment options. Micro‐Abstract This study examined the value of 68Ga‐HBEDD (PSMA‐11; prostate‐specific membrane antigen, PSMA) positron emission tomography (PET) in predicting treatment response and disease progression in 177Lu–PSMA‐617 (Lu‐PSMA) therapy within the context of a phase 2 prospective pilot trial. The study found that a minimum intensity of tumor activity is required on PSMA PET to get a treatment response to Lu‐PSMA therapy.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1016/j.clgc.2018.09.014

Cites

1 of 1 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 1 references

Cited by

Metadata

Authors
Emmett, L., Crumbaker, M., Ho, B., Willowson, K., Eu, P., Ratnayake, L., Epstein, R., Blanksby, A., Horvath, L., Guminski, A., Mahon, K., Gedye, C., Yin, C., Stricker, P., & Joshua, A. M.
Venue
Clinical Genitourinary Cancer
Publisher
Elsevier BV
Published
2019-02
Volume
17
Issue
1
Pages
15-22
ISSN
1558-7673 (ISSN-L)
OpenAlex
W2894392370
Cited by
185
References
1
FWCI
15.12
Type
journal article
Language
en
Open access
closed

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.